Jane Street Group LLC Acquires Shares of 11,852 FibroBiologics, Inc. (NASDAQ:FBLG)

Jane Street Group LLC bought a new position in FibroBiologics, Inc. (NASDAQ:FBLG) in the 3rd quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor bought 11,852 shares of the company’s stock, valued at approximately $37,000.

A number of other large investors have also modified their holdings of FBLG. The Manufacturers Life Insurance Company acquired a new position in FibroBiologics during the 3rd quarter worth approximately $32,000. Mercer Global Advisors Inc. ADV acquired a new position in shares of FibroBiologics during the second quarter worth $51,000. Rhumbline Advisers acquired a new position in shares of FibroBiologics during the second quarter worth $115,000. Symphony Financial Ltd. Co. purchased a new position in shares of FibroBiologics in the third quarter valued at $76,000. Finally, Bank of New York Mellon Corp acquired a new stake in FibroBiologics during the 2nd quarter valued at $342,000.

FibroBiologics Stock Performance

Shares of FibroBiologics stock opened at $1.91 on Friday. FibroBiologics, Inc. has a 1 year low of $1.08 and a 1 year high of $55.00. The firm’s 50-day simple moving average is $2.38 and its 200-day simple moving average is $2.91.

Wall Street Analyst Weigh In

A number of research firms have weighed in on FBLG. D. Boral Capital reissued a “buy” rating and issued a $16.00 price objective on shares of FibroBiologics in a research report on Friday, December 27th. HC Wainwright reissued a “buy” rating and issued a $12.00 price target on shares of FibroBiologics in a report on Wednesday, November 13th. Maxim Group started coverage on FibroBiologics in a research note on Tuesday, September 24th. They set a “buy” rating and a $12.00 price objective for the company. Finally, Rodman & Renshaw began coverage on FibroBiologics in a research report on Thursday, December 12th. They issued a “buy” rating and a $12.00 target price on the stock. Four analysts have rated the stock with a buy rating and one has assigned a strong buy rating to the company’s stock. According to data from MarketBeat.com, the company currently has an average rating of “Buy” and an average target price of $13.00.

FibroBiologics Profile

FibroBiologics, Inc operates as a cell therapy, regenerative medicine company. It is developing a pipeline of treatments and potential cures for chronic diseases using fibroblast cells and fibroblast-derived materials. It holds 150+ U.S. and internationally issued patents/patents pending across various clinical pathways, including disc degeneration, orthopedics, multiple sclerosis, psoriasis, wound healing, reversing organ involution, and cancer.